Nevro Corporation has announced a series of data presentations supporting the use of the company’s high-frequency (HFX) 10kHz spinal cord stimulation (SCS) therapy for patients with chronic pain—set to be presented at this week’s North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas, USA).
A total of 25 scientific abstracts reviewing clinical results for 10kHz therapy, including four podium presentations and 21 posters, will be presented at the conference.
Nevro will host a lunch symposium showcasing the benefits of its artificial intelligence (AI)-enabled HFX iQ system in a presentation on Saturday 20 January. In addition, the company will unveil its new sacroiliac (SI) joint fusion portfolio at exhibit booth #0238.
“Our strong presence at NANS underscores Nevro’s dedication to continuously improving the chronic pain field and providing the best possible pain management solutions to patients,” said Kevin Thornal, the company’s chief executive officer and president. “The growing body of clinical evidence from our 25 scientific abstracts displays the substantial benefits of 10kHz therapy, and we look forward to continuing to treat under-served patient populations suffering from debilitating chronic pain.”
Key sessions highlighted by Nevro, relating to painful diabetic neuropathy (PDN) and the company’s 10kHz therapy, include:
- Main session: “Scientific advances in neuromodulation session one”, on Saturday 20 January
- Concurrent session: “10kHz SCS treatment of PDN: results combining dermatomal dysaesthesias and lower limb sensory assessments”, presented by Nevro senior vice president and chief medical officer David Caraway on Saturday 20 January
- Concurrent session: “Quantifying the neural response to kilohertz SCS using calcium-sensitive imaging”, presented by Nevro director of theoretical research Dongchul Lee on Saturday 20 January
- Main session: “The future is NOW: late-breaking science updates”, Saturday 20 January
- Plenary session: “10kHz SCS treatment of PDN: significant reductions in HbA1c, weight, and pain”, presented by Johnathan Goree (University of Arkansas for Medical Sciences, Little Rock, USA) on Saturday 20 January.
In addition, sessions that the company highlights as relevant to its non-surgical back pain (NSBP) offerings include:
- Main session: “Neuromodulation and athletics. Parallels and lesson”, on Saturday 20 January
- Concurrent session: “Comparing 10kHz SCS efficacy in persistent spinal pain with and without previous spine surgery”, presented by Leonardo Kapural (Carolinas Pain Institute, Winston-Salem, USA) on Saturday 20 January.
